Published online before print December 29, 2005, doi: 10.1161/01.ATV.0000201938.78044.75
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Metformin Inhibits Proinflammatory Responses and Nuclear Factor-
B in Human Vascular Wall Cells
From Donald W. Reynolds Cardiovascular Clinical Research Center (K.I., J.L.Y., A.Z., L.A.M., N.G., U.S., P.L.), Department of Pathology (N.T.), Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass. Current address for U.S.: Cardiovascular Disease, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Conn.
Correspondence to Peter Libby, Cardiovascular Medicine, Brigham and Women’s Hospital, NRB 741, 77 Avenue Louis Pasteur, Boston, MA 02115. E-mail plibby{at}rics.bwh.harvard.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Objective— Metformin may benefit the macrovascular complications of diabetes independently of its conventional hypoglycemic effects. Accumulating evidence suggests that inflammatory processes participate in type 2 diabetes and its atherothrombotic manifestations. Therefore, this study examined the potential action of metformin as an inhibitor of pro-inflammatory responses in human vascular smooth muscle cells (SMCs), macrophages (M
s), and endothelial cells (ECs).
Methods and Results— Metformin dose-dependently inhibited IL-1ß–induced release of the pro-inflammatory cytokines IL-6 and IL-8 in ECs, SMCs, and Ms. Investigation of potential signaling pathways demonstrated that metformin diminished IL-1ß–induced activation and nuclear translocation of nuclear factor-kappa B (NF-
B) in SMCs. Furthermore, metformin suppressed IL-1ß–induced activation of the pro-inflammatory phosphokinases Akt, p38, and Erk, but did not affect PI3 kinase (PI3K) activity. To address the significance of the anti-inflammatory effects of a therapeutically relevant plasma concentration of metformin (20 µmol/L), we conducted experiments in ECs treated with high glucose. Pretreatment with metformin also decreased phosphorylation of Akt and protein kinase C (PKC) in ECs under these conditions.
Conclusions— These data suggest that metformin can exert a direct vascular anti-inflammatory effect by inhibiting NF-B through blockade of the PI3K–Akt pathway. The novel anti-inflammatory actions of metformin may explain in part the apparent clinical reduction by metformin of cardiovascular events not fully attributable to its hypoglycemic action.
This study tested the hypothesis that metformin modulates inflammation in the atherosclerotic plaque by using cells that comprise these lesions. Metformin reduced elaboration of the pro-inflammatory cytokines IL-6 and IL-8 from activated smooth muscle cells, endothelial cells, and macrophages with concomitant impairment of NF-B nuclear activation.
Key Words: atherosclerosis • diabetes • inflammation • interleukins • smooth muscle cell
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Type 2 diabetes mellitus currently comprises 90% to 95% of all diagnosed diabetes, with an alarming increase in incidence among youths.1 Risk of cardiovascular death and stroke increases 2- to 4-fold in diabetic patients, a prominent comorbidity that accounts for 65% of deaths among the growing diabetic population and underscores the important intersection between this metabolic disease and cardiovascular events.1
The concordance between diabetes and cardiovascular disease highlights a multifactorial relationship, implicating hyperglycemia, insulin resistance, hypertension, and dyslipidemia.2 Although glycemic control represents the classical goal of diabetes therapy, the pathogenesis of the vascular complications of diabetes and the metabolic syndrome extend beyond hyperglycemia and glycated proteins.3 Notably, the United Kingdom Prospective Diabetes Study 34 (UKPDS 34) demonstrated that despite similar glucose-lowering effects, administration of metformin reduced all-cause mortality, myocardial infarction, and stroke more than insulin or sulfonylureas (chlorpropamide, glibenclamide).4,5 UKPDS 34 suggested that glucose-lowering properties alone cannot account for the additional cardiovascular benefit, hence the hypothesis that metformin confers vascular benefits beyond its hypoglycemic action.
Metformin, a biguanide family member commonly used in treatment for type 2 diabetes, appears to increase liver and peripheral tissue sensitivity to insulin as well as reduce hepatic glucose production; however, its exact mechanism remains unclear.2,6 Previous studies show early evidence of metformin actions beyond its effects on glucose metabolism, including reduction of plasminogen activator inhibitor (PAI)-1, von Willebrand factor (vWF), and smooth muscle cell (SMC) contractility via either agonist-induced increase in intracellular [Ca2+] or a secondary increase in nitric oxide.7–9 Recent clinical studies further suggest that metformin may alter inflammation as determined by decreased inflammatory markers in plasma, including soluble intercellular adhesion molecule, vascular cell adhesion molecule-1, macrophage migration inhibitory factor, and C-reactive protein (CRP) in some cases of polycystic ovary syndrome, indicating modulation of inflammation.10–12
In the context of the current concept of atherosclerosis as an inflammatory disorder, studies over the past two decades have established that the nuclear transcription factor-kappa B (NF-B) plays a central role in mediating cytokines, growth factors, receptor signaling proteins, cell adhesion molecules, and other proteins of immunity in cell types resident to the plaque microenvironment, ie, endothelial cells (ECs), SMCs, and macrophages (Ms).13–15 Activation of NF-B transcriptionally activates multiple pro-inflammatory genes, including those that encode the pro-atherogenic cytokines IL-6 and IL-8.16 Of interest to the intersection of atherosclerosis and diabetes, recent studies demonstrate enhanced serum IL-6 in obese type 2 diabetes mellitus patients with a concordant elevation of NF-B and decrease in IB in blood mononuclear cells.17,18 The cytokine IL-8 participates in neutrophil activation and chemotaxis.19 Mice with Ms unable to respond to IL-8 show impaired M recruitment to the atherosclerotic lesion, suggesting a role for IL-8 in monocyte trafficking in vivo.19,20
The present study uses cells that localize in atheroma to test the hypothesis that metformin modulates the inflammatory potential of the atherosclerotic plaque. Metformin reduced elaboration of the pro-inflammatory cytokines IL-6 and IL-8 from activated cells and concomitantly impairs NF-B nuclear activation in vascular SMCs.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
We purchased 1,1-Dimethylbiguanide hydrochloride (metformin), mannitol, EDTA, and trypan blue dye from Sigma (St. Louis, Mo). Recombinant IL-1ß, IL-6, and IL-8, as well as antibody for IL-6 and IL-8 with or without biotinylation, were purchased from Pierce Endogen (Rockford, Ill). Anti-human phospho-Akt, Akt, phospho-JNK, phospho-protein kinase C (PKC), phospho-AMP–activated protein kinase (AMPK), and phospho-p65 were obtained from Cell Signaling (Beverly, Mass). Anti-human phospho-Erk, Erk, phospho-p38, p-38, PKC, p65, and I
B were obtained from Santa Cruz Biotechnology (Santa Cruz, Calif), whereas anti-human GAPDH was obtained from Biodesign (Saco, Me).
Cell Isolation and Culture
Cultured human vascular ECs and SMCs were isolated from saphenous veins as described previously.21–23 Ms were isolated from freshly prepared leukocyte concentrates by density gradient centrifugation using Lymphocyte Separation Medium (ICN Biomedicals, Aurora, Ohio) and subsequent adherence to plastic culture flasks. Ms were cultured for 10 days in RPMI 1640 containing 2% human serum (Atlanta Biologicals, Lawrenceville, Ga).23 All three cell types were cultured in media lacking fetal bovine serum before (12 hours) and during the experiment.23 Culture media and fetal bovine serum contained <40 pg endotoxin/mL as determined by the chromogenic Limulus amoebocyte assay (Associates of Cape Cod, Falmouth, Mass).
Enzyme-Linked Immunosorbent Assay
Enzyme-linked immunosorbent assay (ELISA) was performed as previously described.21
Western Blot Analysis
Western blot analysis was performed as previously described.21 Densitometric analysis of immunoreactive bands used National Institutes of Health Image J (National Institutes of Health) applied to digital images of respective Western blots.
Evaluation of Cell Viability
Cell viability was determined by trypan blue dye exclusion after 12 hours of metformin treatment. Additional experiments monitored cytoplasmic oligonucleosome formation (Roche Applied Science, Indianapolis, Ind).
Immunostaining of NF-B in Cultures of Human SMCs
After fixation with 4% paraformaldehyde in phosphate-buffered saline (PBS), cells were permeabilized by methanol treatment (5 minutes) and blocked with 10% goat serum in PBS. Cells were incubated with primary antibody anti-p65 NF-B before application of Alexa-fluor 594 anti-mouse IgG1 antibody (Molecular Probes, Eugene, Ore). Cells were washed 3 times with PBS between each step. Immunostained cells were visualized with a Nikon IX 710 fluorescence microscope.
PI3-Kinase Activity Assay
The PI3-kinase activity was assayed as previously described.24
Statistical Analysis
Results are shown as mean±SEM. Differences between groups were determined using ANOVA with Bonferroni post hoc test. Two groups were compared using the Student t test. A value of P<0.05 was regarded as a significant difference.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Metformin Inhibits IL-1ß–Induced IL-6 and IL-8 Production in SMCs, ECs, and M
sTo investigate whether metformin modulates inflammatory functions in cells found in atherosclerotic plaques, cultured cells (SMCs, ECs, M
s) were stimulated with IL-1ß (1 ng/mL; 12 hours) under serum-free conditions and then incubated with fresh media in the absence or presence of metformin (1 nmol/L to 1 mmol/L) for 6 hours. Cell culture supernatants were assayed for IL-6 and IL-8 protein levels by ELISA. Unstimulated cultured cells released no IL-6 and IL-8 and, as expected, IL-1ß stimulation markedly induced release of these cytokines. Metformin inhibited IL-1ß–induced IL-6 (Figure 1A) and IL-8 (Figure 1B) release in SMCs, ECs, and Ms in a concentration-dependent manner. Inhibition of IL-6 and IL-8 occurred at metformin concentrations in the nanomolar to micromolar range consistent with those achieved clinically.
|
Metformin Does Not Impair Cell Viability
Metformin did not induce death of SMCs, ECs, or Ms at concentrations up to 10 mmol/L, as determined by trypan blue exclusion and phase contrast micrographic inspection, indicating that toxic effects of metformin do not explain the attenuated inflammatory response (data not shown). Additional studies measuring oligonucleosome formation, an index of apoptosis, in SMCs and ECs support this conclusion (data not shown).
Metformin Limits IL-1ß–Induced NF-B Activation in SMCs
Further experiments explored the molecular mechanisms by which metformin diminishes the inflammatory response in vascular SMCs by analyzing activation of the central pro-inflammatory transcription factor NF-B. Human vascular SMCs pre-incubated with metformin (1 mmol/L; 30 minutes) had markedly attenuated IL-1ß–induced phosphorylation of p65 protein (Figure 2). In accord, metformin also suppressed degradation of IB
, suggesting that metformin may interfere with IL-1ß activation of the NF-B signaling cascade by increasing cytoplasmic sequestration of NF-B by IB (Figure 2). In support of these biochemical observations, immunostaining using anti-NF-B antibody revealed that metformin suppressed nuclear translocation of NF-B (Figure 3).
|
|
Metformin Inhibits the PI3-Kinase/Akt Pathway
To obtain further evidence that metformin could regulate inflammatory pathways, we analyzed the effect of metformin on IL-1ß–induced phosphorylation of Akt (Figure 4A), Erk (Figure 4B), p38 (Figure 4C), and c-Jun N-terminal kinase (JNK) (Figure 4D) in SMCs by Western blotting. Resting SMCs did not contain phosphorylated forms of Akt, Erk, p38, or JNK (data not shown). However, on stimulation with IL-1ß, SMCs showed rapid phosphorylation of Akt, peaking at 10 minutes and beginning to decline by 30 minutes after stimulation (Figure 4A). Pretreatment with metformin decreased phosphorylation with a maximum inhibitory effect of 68%, as observed at 10 minutes after stimulation.
|
Furthermore, stimulation of SMCs with IL-1ß (1 ng/mL) maximally induced the phosphorylation of Erk and p38 at 30 minutes after stimulation (Figure 4B, 4C). Interestingly, pretreatment of SMCs with metformin before addition of IL-1ß inhibited Erk and p38 phosphorylation by 30% and 52%, respectively, at 30 minutes after stimulation as compared with SMCs treated with IL-1ß alone.
Stimulation of SMCs with IL-1ß (1 ng/mL) induced JNKp54 phosphorylation, with maximum phosphorylation at 60 minutes after stimulation (Figure 4D). However, inhibition caused by treatment with metformin occurred at 30 minutes after stimulation when JNKp54 phosphorylation was 42% less than in SMCs treated with IL-1ß alone. Exposure to metformin did not significantly suppress activation of PI3-kinase at 10 minutes after stimulation, suggesting no functional deficit of PI3-kinase (Figure 5). Taken together, these results point to a mode of metformin action downstream of PI3-kinase yet upstream of Akt.
|
Therapeutically Relevant Concentration of Metformin Inhibits Glucose-Induced Inflammation
A recent report demonstrated that treatment of ECs with high glucose (HG) (30 mmol/L) in ECs leads to activation of PI3K and Akt, as well as subsequent NF-B activation.25 To address the importance of the anti-inflammatory effects of a therapeutically relevant plasma concentration of metformin (20 µmol/L), we investigated the effect of metformin on pro-inflammatory signaling in ECs exposed to HG (30 mmol/L). Western blots evaluated the effect of metformin on HG-induced phosphorylation of Akt (Figure 6A) in ECs pretreated with 20 µmol/L metformin for 1 hour and exposed to HG. On stimulation with HG, ECs showed phosphorylation of Akt, but the peak (30 minutes) was delayed compared with IL-1ß stimulation (10 minutes). Pretreatment with metformin decreased Akt phosphorylation at 30 and 60 minutes.
|
Gallo et al showed that metformin prevents glucose-induced PKC activation in ECs.26 We also examined the effect of metformin on phosphorylation of PKC (Figure 6B). Stimulation of ECs with HG induced PKC phosphorylation, with maximum phosphorylation at 30 minutes. Of note, metformin inhibited PKC phosphorylation at 30 and 60 minutes. Although a recent report showed that metformin activates AMPK in ECs,27 we found no AMPK phosphorylation at any time point using a pharmacologically relevant concentration of metformin (data not shown). We further treated ECs with a range of metformin concentrations (2 to 2000 µmol/L) for 1 hour. Western blot analysis revealed that metformin >200 µmol/L could induce AMPK phosphorylation (Figure 6C).
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Metformin enjoys wide use in the management of type 2 diabetes. Clinical trials with metformin have indicated improvement in cardiovascular events in diabetic patients apparently beyond its glucose-lowering properties.4 However, metformin’s possible mechanisms of action beyond glycemic control remain poorly understood. The present study shows a novel anti-inflammatory function of metformin, disclosed by inhibited release of IL-6 and IL-8 from human vascular SMCs, ECs, and M
s. These anti-inflammatory functions occurred at concentrations on the order of plasma levels achieved during conventional clinical regimens in either type 2 diabetics or healthy nondiabetic adults.28 The current study reveals insight into the potential underlying anti-inflammatory mechanisms of metformin, which may contribute to the observed clinical benefits in cardiovascular outcomes. Inflammation undoubtedly participates in coronary heart disease.29 White blood cell count and levels of CRP predict the incidence of type 2 diabetes.30 Furthermore, obesity elevates levels of pro-inflammatory cytokines, considered mediators of increased cardiovascular morbidity in these patients.31 Cytokines such as IL-8 likely contribute to monocyte recruitment and adhesion to ECs in atherosclerosis, whereas IL-6 drives the acute phase response.19 This study demonstrates that metformin inhibits IL-1ß–induced IL-6 and IL-8 expression, showing mechanisms by which treatment with metformin may attenuate inflammation.
Compelling evidence suggests that in SMCs, cytokines mediate a range of their pro-inflammatory effects by activating NF-B.32 SMCs in human atherosclerotic plaques display activation of this multipotent pro-inflammatory transcriptional regulator.33,34 Therefore, limiting NF-B activation in plaques could represent a molecular mechanism by which metformin modulates inflammatory responses to IL-1ß. Metformin suppressed cytokine-induced NF-B–dependent gene transcription in the present study, caused by modulation of cytokine-induced IB degradation and NF-B nuclear translocation. These findings suggest a novel anti-inflammatory mechanism for metformin, ie, inhibition of NF-B activation.
To elucidate the molecular mechanisms leading to inhibition of NF-B activation by metformin, we explored IL-1 signaling cascades including 3 distinct types of mitogen-activated protein (MAP) kinases (p38, JNK, and Erk).35 IL-1–stimulated SMCs showed activation of all three MAP kinase pathways studied. The MAP 3-kinase family MEKK activates the protein kinase MEK, which subsequently activates p38, JNK, or Erk.36 Once activated, MAP kinases translocate to the nucleus and activate transcription factors. The p38 kinase regulates various transcription factors, including NF-B, considered a central hub of pro-inflammatory gene regulation in atherosclerosis.37 Moreover, the transcriptional activity of NF-B p65 links with versatile coactivator proteins such as p300, CBP, TFIIB, and TBP.38,39 Thus, p38 kinase may regulate these coactivators to facilitate NF-B–dependent gene expression. We observed that metformin inhibited IL-1–induced p38 phosphorylation in SMCs.
Most cells express 2 JNK isoforms, JNK1 and JNK2, which share similar modes of regulation.40 Activation of JNK greatly enhances c-Jun transcriptional activity and expression of the AP-1 target gene.41 Moreover, recent data demonstrated that AP-1 participates importantly in the regulation of the IL-6 gene in IL-1–stimulated cells.42 In our study, metformin also inhibited IL-1–induced phosphorylation of JNK, suggesting that blocking JNK activation contributed to the inhibition of cytokine expression, potentially via c-Jun or AP-1.
Previous studies showed that Akt and Erk1/2 act upstream of NF-B.43,44 Akt also associates directly with IKK, and activates IKK- via phosphorylation at Thr-2. Mutation of this amino acid blocks Akt-induced IKK- phosphorylation and NF-B activation.43 However, Erk1/2 activation induces IB degradation.44 These reports support our findings that metformin suppressed the phosphorylation of Akt and Erk1/2 with consequent inhibition of NF-B translocation and of IB degradation.
This study demonstrates that metformin may suppress the phosphorylation of all three MAP kinases (p38, JNK, and Erk) and Akt. Therefore, we investigated PI3-kinase phosphorylation because of its established role as an upstream activator of Akt.43 Metformin did not significantly suppress phosphorylation of PI3-kinase targets, inconsistent with a functional deficit of PI3-kinase. Taken together, these results indicate that metformin blocks pro-inflammatory signal transduction in SMCs via NF-B downstream of PI3-kinase by suppressing Akt, Erk1/2, and, finally, NF-B translocation.
Our signaling studies used metformin (1 mmol/L) at a level that exceeds its therapeutic plasma concentration (Cmax 20 µmol/L). Further experiments therefore investigated the effect of a therapeutically relevant plasma concentration of metformin (20 µmol/L) on Akt phosphorylation in ECs exposed to HG. Pretreatment with metformin (20 µmol/L) decreased Akt phosphorylation at 30 and 60 minutes, establishing that inhibition of pro-inflammatory signaling occurs at therapeutic plasma concentrations of metformin and in support of the potential clinical relevance of these "pleiotropic" effects of the agent. Interestingly, metformin also inhibited PKC activation in response to HG, concordant with a recent report.26 PKC activation in EC leads to extracellular matrix accumulation, increased endothelial permeability, and basement membrane thickening, as well as EC vasodilator dysfunction.45 Thus, the inhibition of PKC activation may provide an additional mechanism for metformin that mediates its apparently beneficial cardiovascular effects in patients with diabetes. Several previous reports have demonstrated activation of AMPK by metformin in various cell types including vascular cells.27,46 Others have shown that AMPK activation reduces phosphorylation of Akt and Erk1/2 in SMCs.47 Unexpectedly, metformin (20 µmol/L) did not induce AMPK phosphorylation in our study. Our data demonstrated that AMPK phosphorylation requires >200 µmol/L metformin.
The plasma levels of metformin may underestimate its local penetration and concentration in tissue.48 A recent study in rats demonstrated that metformin can accumulate several-fold within tissues.49 Positively charged at physiological pH, metformin can accumulate simultaneously as much as 1000-fold inside mitochondria.50 Thus, concentrations used here may bear relevance to the plaque microenvironment. The present novel findings that metformin inhibits inflammatory pathways implicated in atherosclerosis shed new light on the mechanisms that underlie this agent’s reduction of macrovascular complications of diabetes incompletely explained by its effects on glycemia.
|
Acknowledgments |
|---|
This work was supported by grants from the Donald W. Reynolds Foundation to P. Libby, the National Institutes of Health (HL66086) to U. Schönbeck, the National Defense Medical College (H14) to K. Isoda, the American Heart Association (Scholar in Stroke and Cardiovascular Disease) to J.L. Young, Deutsche Forschungsgemeinschaft (ZI743/1-1) to A. Zirlik, and the Ernst Schering Research Foundation to N. Gerdes. We thank Elissa Simon-Morrisey, Michelle Rodrigue, and Nomeda Vaisviliene for their skillful assistance in this project. We also thank Karen Williams for her editorial expertise.
Received April 7, 2005; accepted December 15, 2005.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2004.
2. Libby P. Metformin and vascular protection: a cardiologist’s view. Diabetes Metab. 2003;29:6S117–6S120. http://www.cdc.gov/diabetes/pubs/pdf/rdfs_2003.pdf.
3. Libby P, Plutzky J. Diabetic macrovascular disease. The glucose paradox. Circulation. 2002; 106: 2760–2763.
4. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352: 854–865.[CrossRef][Medline] [Order article via Infotrieve]
5. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346: 393–403.
6. Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs. 1999; 58 (Suppl 1): 31–39;discussion 75–82.[CrossRef]
7. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care. 1993; 16: 621–629.[Abstract]
8. Dominguez LJ, Davidoff AJ, Srinivas PR, Standley PR, Walsh MF, Sowers JR. Effects of metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rat vascular smooth muscle. Endocrinology. 1996; 137: 113–121.[Abstract]
9. Bhalla RC, Toth KF, Tan E, Bhatty RA, Mathias E, Sharma RV. Vascular effects of metformin. Possible mechanisms for its antihypertensive action in the spontaneously hypertensive rat. Am J Hypertens. 1996; 9: 570–576.[CrossRef][Medline] [Order article via Infotrieve]
10. Caballero AE, Delgado A, Aguilar-Salinas CA, Herrera AN, Castillo JL, Cabrera T, Gomez-Perez FJ, Rull JA. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab. 2004; 89: 3943–3948.
11. Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003; 88: 4649–4654.
12. Dandona P, Aljada A, Ghanim H, Mohanty P, Tripathy C, Hofmeyer D, Chaudhuri A. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab. 2004; 89: 5043–5047.
13. Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol. 2001; 12: 383–389.[CrossRef][Medline] [Order article via Infotrieve]
14. Bavendiek U, Libby P, Kilbride M, Reynolds R, Mackman N, Schonbeck U. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem. 2002; 277: 25032–25039.
15. Monaco C, Paleolog E. Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res. 2004; 61: 671–682.
16. Thurberg BL, Collins T. The nuclear factor-kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis. Curr Opin Lipidol. 1998; 9: 387–396.[CrossRef][Medline] [Order article via Infotrieve]
17. Kado S, Nagase T, Nagata N. Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus. Acta Diabetol. 1999; 36: 67–72.[CrossRef][Medline] [Order article via Infotrieve]
18. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation. 2004; 110: 1564–1571.
19. Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA Jr, Luster AD, Luscinskas FW, Rosenzweig A. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 1999; 398: 718–723.[CrossRef][Medline] [Order article via Infotrieve]
20. Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest. 1998; 101: 353–363.[Medline] [Order article via Infotrieve]
21. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells and macrophages: implications for atherogenesis. J Exp Med. 2002; 195: 245–257.
22. Sukhova GK, Schonbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, Libby P. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation. 1999; 99: 2503–2509.
23. Schonbeck U, Mach F, Sukhova GK, Atkinson E, Levesque E, Herman M, Graber P, Basset P, Libby P. Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J Exp Med. 1999; 189: 843–853.
24. Marx N, Walcher D, Raichle C, Aleksic M, Bach H, Grub M, Hombach V, Libby P, Zieske A, Homma S, Strong J. C-peptide colocalizes with macrophages in early atherosclerosis lesions of diabetic subjects and induces monocyte chemotaxis in vitro. Arterioscler Thromb Vasc Biol. 2004; 24: 540–545.
25. Sheu ML, Ho FM, Yang RS, Chao KF, Lin WW, Lin-Shiau SY, Liu S-H. High glucose induces human endothelial cell apoptosis through a phosphoinositide 3-kinase-regulated cyclooxygenase-2 pathway. Arterioscler Thromb Vasc Biol. 2005; 25: 539–545.
26. Gallo A, Ceolotto G, Pinton P, Iori E, Murphy E, Rutter GA, Rizzuto R, Semplicini A, Angelo A. Metformin prevents glucose-induced protein kinase C-ß2 activation in human umbilical vein endothelial cells through an antioxidant mechanism. Diabetes. 2005; 54: 1123–1131.
27. Zou MH, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WG 4th, Schlattner U, Neumann D, Brownlee M, Freeman MB, Goldman MH. Activation of the AM-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem. 2004; 279: 43940–43951.
28. Glucophage (metformin hydrochloride tablets) Prescription Insert. Bristol-Myers Squibb Company; New York, NY.
29. Libby P. Atherosclerosis: A New View. Scientific Am. 2002; 286: 47–55.
30. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001; 286: 327–334.
31. Das U. Is obesity an inflammatory condition? Nutrition. 2001; 17: 953–966.[CrossRef][Medline] [Order article via Infotrieve]
32. Lawrence R, Chang LJ, Siebenlist U, Bressler P, Sonenshein GE. Vascular smooth muscle cells express a constitutive NF-kappa B-like activity. J Biol Chem. 1994; 269: 28913–28918.
33. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest. 1996; 97: 1715–1722.[Medline] [Order article via Infotrieve]
34. Bourcier T, Sukhova G, Libby P. The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem. 1997; 272: 15817–15824.
35. Cobb MH, Goldsmith EJ. How MAP kinases are regulated. J Biol Chem. 1995; 270: 14843–14846.
36. Derijard B, Raingeaud J, Barrett T, Wu IH, Han J, Ulevitch RJ, Davis RJ. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science. 1995; 267: 682–685.
37. Vanden Berghe W, Plaisance S, Boone E, De Bosscher K, Schmitz ML, Fiers W, Haegeman G. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J Biol Chem. 1998; 273: 3285–3290.
38. Gerritsen ME, Williams AJ, Neish AS, Moore S, Shi Y, Collins T. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci U S A. 1997; 94: 2927–2932.
39. Kaszubska W, Hooft van Huijsduijnen R, Ghersa P, DeRaemy-Schenk AM, Chen BP, Hai T, DeLamarter JF, Whelan J. Cyclic AM-independent ATF family members interact with NF-kappa B and function in the activation of the E-selectin promoter in response to cytokines. Mol Cell Biol. 1993; 13: 7180–7190.
40. Guan Z, Tetsuka T, Baier LD, Morrison AR. Interleukin-1 beta activates c-jun NH2-terminal kinase subgroup of mitogen-activated protein kinases in mesangial cells. Am J Physiol. 1996; 270: F634–F641.
41. Smeal T, Binetruy B, Mercola D, Grover-Bardwick A, Heidecker G, Rapp UR, Karin M. Oncoprotein-mediated signalling cascade stimulates c-Jun activity by phosphorylation of serines 63 and 73. Mol Cell Biol. 1992; 12: 3507–3513.
42. Hungness ES, Pritts TA, Luo GJ, Sun X, Penner CG, Hasselgren PO. The transcription factor activator protein-1 is activated and interleukin-6 production is increased in interleukin-1beta-stimulated human enterocytes. Shock. 2000; 14: 386–391.[Medline] [Order article via Infotrieve]
43. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999; 401: 82–85.[CrossRef][Medline] [Order article via Infotrieve]
44. Hoshi S, Goto M, Koyama N, Nomoto K, Tanaka H. Regulation of vascular smooth muscle cell proliferation by nuclear factor-kappaB and its inhibitor, I-kappaB. J Biol Chem. 2000; 275: 883–889.
45. Way KJ, Katai N, King GL. Protein kinase C and the development of diabetic vascular complications. Diabet Med. 2001; 18: 945–959.[CrossRef][Medline] [Order article via Infotrieve]
46. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, Kahn BB. Leptin stimulates fatty-acid oxidation by activating AM-activated protein kinase. Nature. 2002; 415: 339–343.[CrossRef][Medline]
[Order article via Infotrieve]
47. Rubin LJ, Magliola L, Feng X, Jones AW, Hale CC. Metabolic activation of AM kinase in vascular smooth muscle. J Appl Physiol. 2005; 98: 296–306.
48. Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica. 1994; 24: 49–57.[Medline] [Order article via Infotrieve]
49. Wilcock C, Wyre ND, Bailey CJ. Subcellular-distribution of metformin in rat-liver. J Pharm Pharmacol. 1991; 43: 442–444.[Medline] [Order article via Infotrieve]
50. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000; 348: 607–614.
This article has been cited by other articles:
 |
|
 |
|
  N. Nath, M. Khan, M. K. Paintlia, M. N. Hoda, and S. Giri Metformin Attenuated the Autoimmune Disease of the Central Nervous System in Animal Models of Multiple Sclerosis J. Immunol., June 15, 2009; 182(12): 8005 - 8014. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Palomba, A. Falbo, F. Zullo, and F. Orio Jr. Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review Endocr. Rev., February 1, 2009; 30(1): 1 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhao, J. W. Zmijewski, E. Lorne, G. Liu, Y.-J. Park, Y. Tsuruta, and E. Abraham Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury Am J Physiol Lung Cell Mol Physiol, September 1, 2008; 295(3): L497 - L504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S Lund, L. Tarnow, C. D A Stehouwer, C. G Schalkwijk, T. Teerlink, J. Gram, K. Winther, M. Frandsen, U. M Smidt, O. Pedersen, et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes Eur. J. Endocrinol., May 1, 2008; 158(5): 631 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Fleischman, S. E. Shoelson, R. Bernier, and A. B. Goldfine Salsalate Improves Glycemia and Inflammatory Parameters in Obese Young Adults Diabetes Care, February 1, 2008; 31(2): 289 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Heutling, H. Schulz, I. Nickel, J. Kleinstein, P. Kaltwasser, S. Westphal, F. Mittermayer, M. Wolzt, K. Krzyzanowska, H. Randeva, et al. Asymmetrical Dimethylarginine, Inflammatory and Metabolic Parameters in Women with Polycystic Ovary Syndrome before and after Metformin Treatment J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 82 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Guzik and D. G. Harrison Endothelial NF-{kappa}B As a Mediator of Kidney Damage: The Missing Link Between Systemic Vascular and Renal Disease? Circ. Res., August 3, 2007; 101(3): 227 - 229. [Full Text] [PDF]
|
|
|
|
|
|
Y. Takemura, Y. Osuga, O. Yoshino, A. Hasegawa, T. Hirata, Y. Hirota, E. Nose, C. Morimoto, M. Harada, K. Koga, et al. Metformin Suppresses Interleukin (IL)-1{beta}-Induced IL-8 Production, Aromatase Activation, and Proliferation of Endometriotic Stromal Cells J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3213 - 3218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Orio, F. Manguso, S. Di Biase, A. Falbo, F. Giallauria, D. Labella, A. Tolino, G. Lombardi, A. Colao, and S. Palomba Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study Eur. J. Endocrinol., July 1, 2007; 157(1): 69 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. W Campbell The role of metformin and pioglitazone in early combination treatment of type 2 diabetes mellitus The British Journal of Diabetes & Vascular Disease, September 1, 2006; 6(5): 207 - 215. [Abstract] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||